Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Christopher Hill has been appointed as both CEO and CFO of Adaptimmune, succeeding Adrian Rawcliffe who departed as part of the company's restructuring efforts. - The company's board has been significantly reduced to three members following the resignation of six directors, with Lawrence Alleva taking over as Chairman from David Mott. - Adaptimmune voluntarily delisted from Nasdaq in October 2025 and is now trading on the OTC Pink market, with deregistration expected to become effective around January 26, 2026. - The restructuring follows the July 2025 divestiture of TECELRA and other key cell therapy assets to US WorldMeds, leaving Adaptimmune to focus on maximizing value from remaining PRAME and CD70-targeted programs.
- Adaptimmune's TECELRA (afamitresgene autoleucel) becomes the first engineered cell therapy approved in the U.S. for solid tumors, specifically targeting synovial sarcoma. - The approval represents the first new treatment option in over a decade for synovial sarcoma, a rare soft tissue cancer primarily affecting young adults. - Adaptimmune's second T cell therapy, lete-cel, achieved its primary endpoint in a pivotal Phase II trial for advanced synovial sarcoma and myxoid/round cell liposarcoma. - The company plans to submit a rolling Biologics License Application to the FDA by the end of 2025 for lete-cel, positioning for a potential second sarcoma approval.
- Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development. - FDA grants Orphan Drug Designation to Actuate Therapeutics' elraglusib for soft tissue sarcoma treatment, highlighting its potential to address unmet needs in this rare cancer. - Novel approaches include tumor-targeting antibody-cytokine fusion proteins, intratumoral administration techniques, and GSK-3β inhibition, offering hope for improved outcomes in this challenging disease.
- The ASGCT Q3 2024 report highlights the continued expansion of the gene and cell therapy field, marked by increasing clinical trials and diversification into non-oncology indications. - FDA approved Adaptimmune Therapeutics’ cell therapy afamitresgene autoleuce (Tecelra) for synovial sarcoma, underscoring advancements in treatment options. - Startup financing in the sector has rebounded, indicating renewed investor confidence and support for new programs in cell and gene therapy. - The report indicates a robust pipeline with therapies advancing through clinical trial phases, suggesting a promising future for patient access to innovative treatments.
• Syros Pharmaceuticals' tamibarotene, combined with azacitidine, did not meet the primary endpoint of complete response (CR) in a Phase III trial for myelodysplastic syndrome (MDS) patients. • The SELECT-MDS-1 trial showed a CR rate of 23.8% in the tamibarotene arm versus 18.8% in the placebo arm, with a non-statistically significant p-value of 0.2084. • Syros is currently analyzing the data to determine the next steps for the development program. • Adaptimmune reported positive results from a pivotal study for its second candidate, lete-cel, with plans for a rolling BLA filing in 2025.
- The FDA has approved Tecelra, a TCR-T cell therapy developed by Adaptimmune Therapeutics, marking the first TCR therapy for solid tumors, specifically unresectable or metastatic synovial sarcoma. - Tecelra targets the MAGE-A4 antigen, which is expressed in several tumors but absent in healthy tissues, offering a novel approach compared to CAR-T therapies by recognizing intracellular antigens. - Clinical trial results showed an overall response rate of 43% in synovial sarcoma patients, with 17% sustaining response for at least 12 months, providing renewed optimism for those with limited options. - While effective, Tecelra's use requires careful monitoring due to potential side effects like cytokine release syndrome (CRS), neurotoxicity, and hematologic toxicity, as highlighted in the FDA's boxed warning.
- The FDA granted accelerated approval to Adaptimmune's afami-cel (Tecelra) for unresectable or metastatic synovial sarcoma in patients who have received prior chemotherapy. - Risk Evaluation and Mitigation Strategies (REMS) for autologous CAR-T immunotherapies were modified by the FDA to reduce the burden on healthcare systems. - A clinical hold on 4D Molecular Therapeutics' Fabry disease gene therapy 4D-310 trial was lifted, with plans to resume enrollment before the end of 2024. - Biosyngen's CAR-T therapy BRG01 has been cleared by the FDA for a pivotal phase 2 clinical trial in patients with Epstein-Barr virus (EBV)-positive relapsed/metastatic nasopharyngeal carcinoma.
